Rosuvastatin for Preventing Complications in Renal Ablation

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to test the hypothesis that twice overnight high-dose rosuvastatin loading before RNA followed by 3-month treatment with regular doses of rosuvastatin can reduce both the acute and late renal artery damage.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Roma La Sapienza
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Primary and idiopathic cause of resistant arterial hypertension defined as persistent systolic blood pressure persistent systolic blood pressure - 160 mm Hg, with at least established three antihypertensive medication (including diuretics)

• Patients with allergies to antihypertensive drugs

• Able to understand and willing to sign the informed CF

Exclusion Criteria:

• Glomerular filtration rate <45 mL/min

• LDL Cholesterol >130 mg/dl

• Presence of coronary artery disease

• History of myopathy or elevated creatine kinase levels

• History of Impaired liver function and/or elevated ALT and/or AST levels

• Women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before CT